$MRK Recent News Merck, McDonald's are top decli

$MRK Recent News

Merck, McDonald's are top decliners in Dow index 18 min ago - Polya Lesova
Cuts, stock buyback, acquisition combine to boost Forest shares 11:09 a.m. Dec. 2, 2013 - blogs.marketwatch.com
Merck, J.P. Morgan lead Dow decliners 9:35 a.m. Nov. 13, 2013 - Laura Mandaro
Merck, Cisco lead gainers in Dow industrials 4:03 p.m. Nov. 12, 2013 - Polya Lesova
Bitcoin buying for dummies 3:22 p.m. Nov. 12, 2013 - blogs.marketwatch.com
Planned layoffs up 13.5% in October: Challenger 7:30 a.m. Nov. 6, 2013 - Steve Goldstein
Newscast: S&P 500 notches year's 32nd record high 8:08 p.m. Oct. 28, 2013 - MarketWatch
J.C. Penney, Bristol-Myers top S&P 500 7:08 p.m. Oct. 28, 2013 - Saumya Vaishampayan
S&P up for 8th day in 9; Dow, Nasdaq flat 4:57 p.m. Oct. 28, 2013 - Victor Reklaitis
Newscast: Stocks mixed after lackluster day 4:26 p.m. Oct. 28, 2013 - MarketWatch
Newscast: Car reliability ranks get new members 2:28 p.m. Oct. 28, 2013 - MarketWatch
Merck shares stumble on earnings weakness, talk of divesting assets 10:58 a.m. Oct. 28, 2013 - blogs.marketwatch.com
Merck, down 2.2%, leads Dow average lower 9:34 a.m. Oct. 28, 2013 - Laura Mandaro
Stock futures continue to waver after data 9:30 a.m. Oct. 28, 2013 - Sara Sjolin
Apple is Monday’s stock to watch as results loom 8:21 a.m. Oct. 28, 2013 - Sue Chang
Merck profit down 35% as Singulair sales fall 7:25 a.m. Oct. 28, 2013 - MarketWatch.com
Merck third-quarter profit, revenue fall 7:17 a.m. Oct. 28, 2013 - Saumya Vaishampayan
Merck narrows 2013 EPS guidance; holds sales view 7:10 a.m. Oct. 28, 2013 - Saumya Vaishampayan
Merck Q3 adj. EPS edges down to $0.92 vs. $0.95 7:03 a.m. Oct. 28, 2013 - Saumya Vaishampayan
Merck Q3 sales down to $11.03 bln vs. $11.49 bln 7:03 a.m. Oct. 28, 2013 - Saumya Vaishampayan


Merck, Procter & Gamble Fall as Market Shrugs Off Taper Fears 6 min ago - TheStreet.com
Biotech Stock Predictions 2014: Vertex is Bought, Alexion Sinks, BlueBird Flies And More 11:35 a.m. Today - TheStreet.com
Meet the Preliminary 2014 Dogs of the Dow: Dividends Galore 11:09 a.m. Today - 247WallSt.com
Health Care Heartiest, Gold Funds All Red In November 5:41 p.m. Dec. 3, 2013 - Investors Business Daily
Forest Labs Up on Strategic Initiatives - Analyst Blog 1:25 p.m. Dec. 3, 2013 - Zacks.com
4 Reasons Tonix Could Be A Multi-Bagger 10:30 a.m. Dec. 3, 2013 - Seeking Alpha
Will GlaxoSmithKline Head Higher After Recent Headlines? 8:53 a.m. Dec. 3, 2013 - Wall St. Cheat Sheet
Pharma & Biotech Stock Outlook - Dec 2013 - Zacks Analyst Interviews 4:28 a.m. Dec. 3, 2013 - Zacks.com
Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook 4:28 a.m. Dec. 3, 2013 - Zacks.com
Forest Labs to Cut 500 Jobs in Restructuring 7:31 p.m. Dec. 2, 2013 - WSJ.com
Merck and Seadrill Top GuruFocus Dividend Growers of the Week 4:56 p.m. Dec. 2, 2013 - GuruFocus.com
Merck: The Good, The Bad And The Ugly 2:46 p.m. Dec. 2, 2013 - Seeking Alpha
Today's Momo Momentum Stock To Watch: Merck (MRK) 1:59 p.m. Dec. 2, 2013 - TheStreet.com
Forest Labs acquires rights to schizophrenia treatment from Merck 10:11 a.m. Dec. 2, 2013 - Seeking Alpha
Losing Some Sparkle to Buybacks 3:10 a.m. Nov. 30, 2013 - Barrons.com
Merck's Noxafil Tablets Approved by the FDA - Analyst Blog 11:30 a.m. Nov. 29, 2013 - Zacks.com
Buy Today: Merck & Co Inc's Buy Recommendation Reiterated 9:00 a.m. Nov. 29, 2013 - TheStreet.com
Drug Stocks: Winners, Losers, in Statin Shift 10:41 p.m. Nov. 27, 2013 - Barrons.com
Updated statin guidelines give AstraZeneca the upper hand: Barron's 10:54 a.m. Nov. 27, 2013 - Seeking Alpha
GlaxoSmithKline: What's The Next Growth Driver? 2:38 p.m. Nov. 26, 2013 - Seeking Alpha


Increased Quarterly Dividends, HIV Elimination Efforts, Advanced Treatment Options, and Conference Participations - Research Report on Merck, Varian, Mylan, Achillion, and Abiomed 8:00 a.m. Today - PR Newswire
Intarcia Therapeutics Appoints Nancy Thornberry to Board of Directors 2:37 p.m. Dec. 2, 2013 - PR Newswire
Forest to Acquire U.S. Marketing Rights to Saphris(R) (asenapine) from Merck 9:00 a.m. Dec. 2, 2013 - BusinessWire
EMD Serono's New Spin-off TocopheRx to Focus on Infertility Treatment 8:30 a.m. Dec. 2, 2013 - BusinessWire
FDA Approvals, Stock Price Updates, New Study Results, Conference Schedules and Partnerships - Research Report on Merck, Pharmacyclics, UnitedHealth Group, Medtronic, and AstraZeneca 8:00 a.m. Nov. 29, 2013 - PR Newswire
Merck Announces Increased Quarterly Dividend 2:18 p.m. Nov. 26, 2013 - BusinessWire
FDA Approves Merck's NOXAFIL(R) (posaconazole) Delayed-Release Tablets 9:00 a.m. Nov. 26, 2013 - BusinessWire
Stock Price Movements and Program Launches Reported by Healthcare Companies - Research Report on Merck, Abiomed, Alere, Raptor Pharmaceuticals and West Pharmaceutical Services 8:00 a.m. Nov. 26, 2013 - PR Newswire
SiSense Wins Quarter Million Dollar Prize, Takes Top Honor in "Take the H.E.L.M." Competition 11:30 a.m. Nov. 25, 2013 - PR Newswire
Mondo Guerra and the Merck HIV Educational Campaign I Design Invite the Community to Pledge Action in Honor of World AIDS Day 8:01 a.m. Nov. 25, 2013 - PR Newswire
ARMO BioSciences Initiates Phase 1 Clinical Trial of First-In-Class Cancer Immunotherapy 8:00 a.m. Nov. 25, 2013 - PR Newswire
European Patent Office Issues Decision Regarding Universal Display's Organometallic Iridium Patent 9:01 a.m. Nov. 22, 2013 - BusinessWire
Sixth Annual Biotech Showcase(TM) Returns to San Francisco January 13-15 6:51 p.m. Nov. 21, 2013 - BusinessWire
FDA Approvals, Stock Price Movements, and Study Results - Research Report on Pfizer, Celgene, Merck, Quest Diagnostics, and Pharmacyclics 8:00 a.m. Nov. 21, 2013 - PR Newswire
Merck Consumer Health Turnaround on Track 4:00 a.m. Nov. 21, 2013 - BusinessWire
Critical Alerts For Netflix, Salesforce.com, Goldman Sachs, Merck, and Valero Energy Released By InvestorsObserver 9:31 a.m. Nov. 19, 2013 - PR Newswire
Merck for Mothers Working to End the Tragedy of Women in America Dying in Childbirth and Pregnancy 8:30 a.m. Nov. 19, 2013 - PR Newswire
Additional Interim Data for Merck's Investigational Anti-PD-1 Immunotherapy, MK-3475, Shows Estimated Overall Survival Rate of 81 Percent at One Year in Patients with Advanced Melanoma 12:00 p.m. Nov. 18, 2013 - BusinessWire
Merck Partners With TRUSTe to Become Certified Under APEC Cross Border Privacy Rules 9:00 a.m. Nov. 18, 2013 - Marketwire
Merck's New Drug Application for an Investigational Intravenous (IV) Formulation of NOXAFIL(R) (posaconazole) Receives FDA Priority Review 8:30 a.m. Nov. 18, 2013 - BusinessWire